Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 397

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes

Open access
Valgimigli, Marco, Frigoli, Enrico, Leonardi, Sergio, Rothenbühler, Martina, Gagnor, Andrea, Calabrò, Paolo, Garducci, Stefano, Rubartelli, Paolo, Briguori, Carlo, Andò, Giuseppe, Repetto, Alessandra, Limbruno, Ugo, Garbo, Roberto, Sganzerla, Paolo, Russo, Filippo, Lupi, Alessandro, Cortese, Bernardo, Ausiello, Arturo, Ierna, Salvatore, Esposito, Giovanni, Presbitero, Patrizia, Santarelli, Andrea, Sardella, Gennaro, Varbella, Ferdinando, Tresoldi, Simone, de Cesare, Nicoletta, Rigattieri, Stefano, Zingarelli, Antonio, Tosi, Paolo, van ’t Hof, Arnoud, Boccuzzi, Giacomo, Omerovic, Elmir, Sabaté, Manel, Heg, Dik, Jüni, Peter, Vranckx, Pascal · 2015 · New England Journal of Medicine

Abstract

BACKGROUND: Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome. METHODS: We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated to receive either bivalirudin or unfractionated heparin. Patients in the bivalirudin group were subsequently randomly assigned to receive or not to receive a post-PCI bivalirudin infusion. Primary outcomes for the comparison between bivalirudin and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myocardial infarction, or stroke) and net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event). The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events. RESULTS: The rate of major adverse cardiovascular events was not significantly lower with bivalirudin than with heparin (10.3% and 10.9%, respectively; relative risk, 0.94; 95% confidence interval [CI], 0.81 to 1.09; P=0.44), nor was the rate of net adverse clinical events (11.2% and 12.4%, respectively; relative risk, 0.89; 95% CI, 0.78 to 1.03; P=0.12). Post-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease the rate of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (11.0% and 11.9%, respectively; relative risk, 0.91; 95% CI, 0.74 to 1.11; P=0.34). CONCLUSIONS: In patients with an acute coronary syndrome, the rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin. The rate of the composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion. (Funded by the Medicines Company and Terumo Medical; MATRIX ClinicalTrials.gov number, NCT01433627.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1507854

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 397

Metadata

Authors
Valgimigli, M., Frigoli, E., Leonardi, S., Rothenbühler, M., Gagnor, A., Calabrò, P., Garducci, S., Rubartelli, P., Briguori, C., Andò, G., Repetto, A., Limbruno, U., Garbo, R., Sganzerla, P., Russo, F., Lupi, A., Cortese, B., Ausiello, A., Ierna, S., Esposito, G., Presbitero, P., Santarelli, A., Sardella, G., Varbella, F., Tresoldi, S., de Cesare, N., Rigattieri, S., Zingarelli, A., Tosi, P., van ’t Hof, A., Boccuzzi, G., Omerovic, E., Sabaté, M., Heg, D., Jüni, P., & Vranckx, P.
Venue
New England Journal of Medicine
Published
2015-09-10
Volume
373
Issue
11
Pages
997-1009
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1278248171
Cited by
397
References
20
FWCI
43.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. https://app.cochat.ai/papers/10.1056/nejmoa1507854
The paper
Valgimigli, M., Frigoli, E., Leonardi, S., Rothenbühler, M., Gagnor, A., Calabrò, P., Garducci, S., Rubartelli, P., Briguori, C., Andò, G., Repetto, A., Limbruno, U., Garbo, R., Sganzerla, P., Russo, F., Lupi, A., Cortese, B., Ausiello, A., Ierna, S., . . . Vranckx, P. (2015). Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1507854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.